Our ocular research center is a one-of-a-kind model. It is the first and only combined eye bank and ocular research center in the world. Our research center empowers researchers to conduct real-time studies of healthy and diseased ocular tissue. This breakthrough model answers a critical need by providing normal and diseased human eye tissue to advance our understanding of events that lead to blindness. We collaborate with industry and leading institutions to develop a new pre-clinical research model offering unparalleled quality and volumes of human ocular tissue and unique research facilities for pharmaceutical or medical device studies.
SIG Session 246: “Importance and Multiple Uses of Human Donor Eye Tissues in Ophthalmic Research”
Samirkumar R. Patel1, Lousie Bergman2, Lennart C. Berglin2, Damian E. Berezovsky3, Xi Wang3, Jason K. Woody4, Mark R. Prausnitz1, Henry F. Edelhauser3
Gary SL Peh1, Kah Peng Th1, Fei Yi Wu1, Donald T Tan1,2, Jodhbir S Mehta1
Olan Suwan-apichon, MD,*† Johann M. G. Reyes, MD,* Neil B. Griffin, MD,‡ Jerry Barker, BS,‡ Patrick Gore, RN,§ and Roy S. Chuck, MD, PhD
Hyung Cho1, Sunju Park1, Alan Fong1, David C. Gritz1, Cheng Zhang1, Alexandra Herzlich1, Gibran Mian1, Patrick Gore2, Ashley Morganti2, Roy Chuck1.
With our model of ocular research, we seek to become a magnet to attract the leading researchers and scientific talent and contribute to the discovery of new breakthrough cures for blinding eye diseases. Click on the links to our partners or contact us to become a partner.
What do Opinion Leaders say about The Ocular Research Center?
“The benefit of conducting studies at the Lions Eye Institute for Trasplant and Research is our ability to obtain human eyes within two to four hours of post-mortem time.”
“Our current studies are evaluating the distribution of various drugs and antibodies used in the treatment of AMD following a single microneedle injection into the suprachoridal space. These studies will show the similarities and/or differences in drug delivery compared to rabbit and pig eyes.”
—Dr. Henry Edelhauser, Professor at Emory University Eye Center
“Through LEITR, we will now have an unprecedented ability to access ocular tissue, which will undoubtedly facilitate new discoveries and future therapies.”
—Mark S. Humayun, MD, PhD, Cornelius Pings Professor of Biomedical Sciences, Professor of Ophthalmology, Biomedical Engineering, Cell and Neurobiology Doheny Eye Institute, University of South California
Contact us at email@example.com to discuss your research needs.